SG11202000881VA - Adjuvant therapy for use in prostate cancer treatment - Google Patents

Adjuvant therapy for use in prostate cancer treatment

Info

Publication number
SG11202000881VA
SG11202000881VA SG11202000881VA SG11202000881VA SG11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA
Authority
SG
Singapore
Prior art keywords
prostate cancer
cancer treatment
adjuvant therapy
adjuvant
therapy
Prior art date
Application number
SG11202000881VA
Inventor
F M J Debruyne
Original Assignee
Fund Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Sa filed Critical Fund Sa
Publication of SG11202000881VA publication Critical patent/SG11202000881VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SG11202000881VA 2017-08-01 2018-02-23 Adjuvant therapy for use in prostate cancer treatment SG11202000881VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17184320 2017-08-01
PCT/EP2018/054470 WO2019025031A1 (en) 2017-08-01 2018-02-23 Adjuvant therapy for use in prostate cancer treatment

Publications (1)

Publication Number Publication Date
SG11202000881VA true SG11202000881VA (en) 2020-02-27

Family

ID=59520769

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000881VA SG11202000881VA (en) 2017-08-01 2018-02-23 Adjuvant therapy for use in prostate cancer treatment

Country Status (12)

Country Link
US (2) US11771705B2 (en)
EP (1) EP3661520B1 (en)
JP (2) JP2020530031A (en)
CN (1) CN111295192A (en)
BR (1) BR112020002094A2 (en)
CA (1) CA3071660A1 (en)
ES (1) ES2906380T3 (en)
MY (1) MY197942A (en)
PL (1) PL3661520T3 (en)
RU (1) RU2758386C2 (en)
SG (1) SG11202000881VA (en)
WO (1) WO2019025031A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231240B1 (en) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Industrial process for the preparation of high-purity estetrol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ES2346053T3 (en) * 2002-11-08 2010-10-08 Pantarhei Bioscience B.V. STERESIS OF STEROL THROUGH STEROIDS DERIVED FROM ESTRONA.
CA2523830A1 (en) * 2003-04-30 2004-11-11 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
WO2005063276A1 (en) * 2003-12-23 2005-07-14 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
TW200950799A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
JP2012077020A (en) * 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd Combination medicine of gestagen and gnrh antagonist

Also Published As

Publication number Publication date
RU2020108631A (en) 2021-09-02
EP3661520B1 (en) 2021-12-01
WO2019025031A1 (en) 2019-02-07
CA3071660A1 (en) 2019-02-07
BR112020002094A2 (en) 2020-07-28
MY197942A (en) 2023-07-25
JP2020530031A (en) 2020-10-15
US11771705B2 (en) 2023-10-03
JP2023085303A (en) 2023-06-20
CN111295192A (en) 2020-06-16
ES2906380T3 (en) 2022-04-18
PL3661520T3 (en) 2022-03-28
US20230405019A1 (en) 2023-12-21
RU2020108631A3 (en) 2021-09-02
US20200246354A1 (en) 2020-08-06
EP3661520A1 (en) 2020-06-10
RU2758386C2 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
IL290149A (en) Combination therapy for cancer treatment
HK1247129A1 (en) Combination therapy for the treatment of cancer
IL267795A (en) Combination therapy for the treatment of cancer
IL255060A0 (en) Combination therapy for treating cancer
HK1251475A1 (en) Combination therapy for the treatment of cancer
IL282663A (en) Bt1718 for use in treating cancer
PT3609497T (en) Combination therapy for prostate cancer
PL3253208T3 (en) Combination therapies for use in the treatment of breast cancer
IL275517A (en) Methods and combination therapy to treat cancer
IL280830A (en) Conjugates for use in methods of treating cancer
IL266993A (en) Combination therapy for the treatment of cancer
PL3258931T3 (en) Use of cabazitaxel in the treatment of prostate cancer
IL281281A (en) Combination therapy for the treatment of prostate cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
SG11202000881VA (en) Adjuvant therapy for use in prostate cancer treatment
GB201704909D0 (en) Cancer therapy
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
IL253642A0 (en) Combination therapy for the treatment of cancer
GB201711855D0 (en) Cancer therapy
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
EP3706752A4 (en) Combination therapy for cancer treatment
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201704474D0 (en) Combination therapy for treatment of cancer